NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their RightsApril 27, 2026
Share Twitter Facebook LinkedIn Email The John Hancock Multimanager Lifestyle Moderate Portfolio fund produced a positive total return and outpaced the benchmark for Q1 2025. Click here to read the full commentary.Read More
‘Chronically online’ Gen Z turning to these hacks to fight brain rot, reduce social media usageApril 27, 2026